Safety profile of a new generation of cholesterol-lowering drugs / Complaints that a new psoriasis treatment could aggravate the condition / Eye inflammation linked to a novel immunosuppressant for atopic dermatitis.

QuarterWatch™ Reports
An independent perspective on emerging drug risks
QuarterWatch™ is published four times a year as a public service to provide an independent perspective on emerging drug risks. This scientific publication uses as its primary source recently released reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
Browse Issues
QuarterWatch™ Reports
September 2018
Rhabdomyolysis: Severe damage to skeletal muscle | Serotonin or Neuroleptic Malignant Syndrome: Key neurotransmitters disrupted | SJS/TEN: Autoimmune reaction destroys large areas of skin | PML: A deadly viral infection of the brain
QuarterWatch™ Reports
May 2018
How Well Do Antidepressant Drugs Work? Vortioxetine (TRINTELLIX) Case Study • Dispensing Errors, Name Confusion for Breo, Anoro, and other Ellipta Inhalers• Abuse of a Widely Used OTC Drug for Diarrhea
QuarterWatch™ Reports
January 2018
Limited system for removing/replacing expiring implants and IUDs • Emergency contraception reports mostly about abnormal menses • Psychiatric symptoms linked to hormonal contraceptives • Missed dose, thrombotic events top issues for combination oral products
QuarterWatch™ Reports
November 2017
Hallucinations and pimavanserin (NUPLAZID), a new kind of drug for psychosis • Hypotension with sacubitril-valsartan (ENTRESTO) for heart failure
QuarterWatch™ Reports
July 2017
Oral anticoagulants the nation’s top risk of acute injury from drugs • Millions at risk from withdrawal symptoms • FAERS: A key monitoring system suffering from continued neglect
QuarterWatch™ Reports
April 2017
Exploring the link with therapeutic drugs • Emotional problems linked to suvorexant (BELSOMRA) started with missed doses • Very different phosphodiesterase-4 (PDE4) drugs can cause psychiatric problems
QuarterWatch™ Reports
January 2017
Antidepressants, allergy drugs among 87 products with signals for insomnia • Liver failure and antiviral failure with hepatitis C direct-acting drugs • Harms of antipsychotic drugs reappraised
QuarterWatch™ Reports
October 2016
Lessons from why new patch for migraines was withdrawn after nine months • Consumers struggle with the self-injection pen for a new diabetes drug